论文部分内容阅读
据中国证监会信息披露,海利尔药业集团股份有限公司拟于上交所上市,本次公开发行股票不超过3000万股,占公司发行后总股本的比例不低于25%。海利尔药业主营业务为农药制剂、相关原药及中间体的研发、生产和销售。公司目前可生产吡虫啉、啶虫脒、嘧菌酯、噻虫嗪、茚虫威五种农药原药和2-氯-5氯甲基吡啶中间体(生产吡虫啉、啶虫脒原药的主要中间体)。曾参与戊唑醇悬浮剂、联苯菊酯原药等9项国家标准的制定工作。
According to the information disclosure of China Securities Regulatory Commission, Heiliier Pharmaceutical Group Co., Ltd. intends to list on the Shanghai Stock Exchange, the public offering of shares does not exceed 30 million shares, accounting for the total share capital of the company after the ratio of not less than 25%. Heilier medicine main business for the pesticide formulations, the original drug and intermediate research and development, production and sales. The company can produce imidacloprid, acetamiprid, azoxystrobin, thiamethoxam and indoxacarb, and the 2-chloro-5-chloromethylpyridine intermediate (the main intermediate for producing imidacloprid and acetamiprid body). Involved in tebuconazole suspension, bifenthrin original drug 9 national standards development.